Eris
Eris, officially known as Eris Lifesciences, is a prominent player in the Indian pharmaceutical industry, headquartered in India. Founded in 2007, the company has rapidly established itself as a leader in the development and marketing of high-quality generic medications, particularly in the therapeutic areas of diabetes, cardiovascular health, and respiratory diseases. With a strong operational presence across India and expanding international markets, Eris is recognised for its commitment to innovation and quality. The company’s core offerings include a diverse range of formulations that are distinguished by their efficacy and affordability, catering to the needs of healthcare professionals and patients alike. Eris has achieved significant milestones, including a robust portfolio of over 100 products and a growing market share, positioning itself as a trusted name in the pharmaceutical sector.
DitchCarbon Score
How does Eris's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Eris's score of 16 is lower than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Eris's reported carbon emissions
Eris Lifesciences Limited, headquartered in India, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges available from the company. As of now, Eris has not inherited any emissions data from a parent company, nor does it have any cascading targets from initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). This lack of data suggests that Eris may still be in the early stages of developing a comprehensive climate strategy or reporting framework. In the context of the pharmaceutical industry, where sustainability and carbon reduction are increasingly important, Eris's commitment to future climate initiatives remains unclear. The company may need to establish measurable targets and transparent reporting to align with industry standards and stakeholder expectations.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Eris is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
